Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Axitinib, ATC L01EK01

Conclusion of non-exclusive rebate contracts in accordance with §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the aforementioned active substance within the period from 01.07.2025 to 30.06.2027 with the possibility of concluding the contract at any time (open-house model). Medicinal products corresponding to the BfArM list according to § 35 para. 5a SGB V (paediatric medicinal products) are excluded from the open-house procedure.